.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Johnson and Johnson
Accenture
Colorcon
AstraZeneca
Queensland Health
Dow
Farmers Insurance
Mallinckrodt
Healthtrust

Generated: December 12, 2017

DrugPatentWatch Database Preview

TARGRETIN Drug Profile

« Back to Dashboard

When do Targretin patents expire, and when can generic versions of Targretin launch?

Targretin is a drug marketed by Valeant Luxembourg and is included in two NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-five patent family members in seventeen countries and five supplementary protection certificates in five countries.

The generic ingredient in TARGRETIN is bexarotene. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the bexarotene profile page.
Drug patent expirations by year for TARGRETIN

Pharmacology for TARGRETIN

Ingredient-typeRetinoids
Drug ClassRetinoid

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Valeant LuxembourgTARGRETINbexaroteneCAPSULE;ORAL021055-001Dec 29, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Valeant LuxembourgTARGRETINbexaroteneCAPSULE;ORAL021055-001Dec 29, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Valeant LuxembourgTARGRETINbexaroteneGEL;TOPICAL021056-001Jun 28, 2000RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for TARGRETIN

Drugname Dosage Strength RLD Submissiondate
bexaroteneCapsules75 mgTargretin6/6/2011

Non-Orange Book Patents for Tradename: TARGRETIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,780,676 Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors► Subscribe
6,610,883 Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors► Subscribe
7,655,699Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors► Subscribe
6,320,074 Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors► Subscribe
6,043,279 Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TARGRETIN

Country Document Number Estimated Expiration
Japan3727334► Subscribe
Australia4118893► Subscribe
Germany69327255► Subscribe
Spain2139063► Subscribe
Luxembourg90803► Subscribe
Austria187434► Subscribe
Germany69333894► Subscribe
Greece3030104► Subscribe
Australia6225894► Subscribe
Germany69333371► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TARGRETIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C013/2001Ireland► SubscribeSPC013/2001: 20031205, EXPIRES: 20160328
2001 00032Denmark► Subscribe
C0027France► SubscribePRODUCT NAME: BEXAROTENE; REGISTRATION NO/DATE: EU/1/01/178/001 20010329
00054Netherlands► SubscribePRODUCT NAME: BEXAROTENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF IN DE VORM VAN EEN ESTER MET EEN HYDROXYVER- BINDING MET DE FORMULE R9OH, WAARIN R9 EEN; NAT. REGISTRATION NO/DATE: EU/1/01/178/001 20010329; FIRST REGISTRATION: EU/1/01/178/001 20010329
C/GB01/041United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB01/041 GRANTED TO EISAI R + D MANAGEMENT., LTD. IN RESPECT OF THE PRODUCT BEXAROTENE (4-(1-(3, 5, 5, 8, 8-PENTAMETHYL-5, 6, 7, 8-TETRAHYDRO-2-NAPHTHALENYL)VINYL)BENZOIC ACID), WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 6469 DATED 15/05/2013 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 01/04/2016.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Mallinckrodt
Covington
Moodys
US Department of Justice
Fuji
US Army
Deloitte
Johnson and Johnson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot